The market expected another clinical-stage loss, but the reported EPS miss was tangible. The published Q2 consensus was approximately -$0.65 per share; Jade reported -$0.76, a roughly $0.11 shortfall. There is no revenue comparison because Jade remains pre-commercial.
| Metric | Q2 2026 | Q2 2025 / expectation |
|---|---|---|
| Net loss | $55.8 million | $32.1 million (Income Statement) |
| Net loss per common share | -$0.76 | -$0.86 / consensus ~-$0.65 |
| R&D expense | $50.1 million | $22.5 million (Income Statement) |
| G&A expense | $8.9 million | $5.2 million (Income Statement) |
| Cash, cash equivalents and investments | $461.2 million | $336.2 million at Dec. 31, 2025 (Balance Sheet) |
| Expected cash runway | Into Q4 2028 | Previously into 1H 2028 (Cash Position) |
The operating miss reflects deliberate pipeline acceleration, not a weakening business model. R&D more than doubled year over year to $50.1 million, driven by clinical activity, manufacturing work, milestone payments and higher stock compensation; G&A also rose to $8.9 million. That spending produced a larger loss, but the company has no product revenue against which to judge operating leverage. (Income Statement)
The clinical update itself is better than the routine earnings headline. JADE101 produced approximately 70% mean IgA reduction after one 700 mg dose, with durability supporting a potential every-12-week maintenance schedule, and the Phase 2 trial is underway. The planned registrational Phase 3 start in the first half of 2027 is consistent with the prior development path rather than a newly accelerated milestone. (Pipeline and Corporate Updates)
JADE301 is the clearest incremental pipeline improvement. The company now expects to begin its Phase 1 healthy-volunteer trial in Q4 2026, earlier than the previously communicated 1H 2027 target. JADE201 also has begun dosing in rheumatoid arthritis, broadly matching the previously signaled Q2 2026 milestone. (Pipeline and Corporate Updates)
Funding risk is reduced, but the improvement came with dilution. Cash increased to $461.2 million following a $172.5 million public offering, extending the stated runway from the first half of 2028 to Q4 2028. That strengthens execution capacity through several 2027 data milestones, but the financing also expands the share base; approximately 83.9 million common shares and equivalents were outstanding at quarter-end. (Cash Position; Balance Sheet)
Net read: the quarter was clinically constructive but financially below expectations. The JADE101 data and earlier JADE301 timetable improve the development story, while the EPS miss and sharply higher cash burn offset part of that benefit. The most important clinical JADE101 data had already been announced before this filing, so the filing mainly confirms progress and updates timing rather than introducing an entirely new surprise.
Read the original 8-K on SEC EDGAR ↗